- Home
- ZENV vs ZURA Comparison
ZENV vs ZURA Comparison
Compare ZENV & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- ZURA
- Stock Information
- Founded
- ZENV 2005
- ZURA 2022
- Country
- ZENV Brazil
- ZURA United States
- Employees
- ZENV N/A
- ZURA N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENV Technology
- ZURA Health Care
- Exchange
- ZENV Nasdaq
- ZURA Nasdaq
- Market Cap
- ZENV 79.2M
- ZURA 69.9M
- IPO Year
- ZENV 2021
- ZURA N/A
- Fundamental
- Price
- ZENV $1.49
- ZURA $1.18
- Analyst Decision
- ZENV
- ZURA Buy
- Analyst Count
- ZENV 0
- ZURA 7
- Target Price
- ZENV N/A
- ZURA $14.33
- AVG Volume (30 Days)
- ZENV 87.2K
- ZURA 709.5K
- Earning Date
- ZENV 07-02-2025
- ZURA 08-08-2025
- Dividend Yield
- ZENV N/A
- ZURA N/A
- EPS Growth
- ZENV N/A
- ZURA N/A
- EPS
- ZENV N/A
- ZURA N/A
- Revenue
- ZENV $181,911,572.00
- ZURA N/A
- Revenue This Year
- ZENV $8.58
- ZURA N/A
- Revenue Next Year
- ZENV $8.83
- ZURA N/A
- P/E Ratio
- ZENV N/A
- ZURA N/A
- Revenue Growth
- ZENV 23.99
- ZURA N/A
- 52 Week Low
- ZENV $1.02
- ZURA $0.97
- 52 Week High
- ZENV $3.03
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- ZENV 44.62
- ZURA 48.73
- Support Level
- ZENV $1.45
- ZURA $1.00
- Resistance Level
- ZENV $1.59
- ZURA $1.22
- Average True Range (ATR)
- ZENV 0.16
- ZURA 0.08
- MACD
- ZENV -0.01
- ZURA -0.00
- Stochastic Oscillator
- ZENV 16.96
- ZURA 52.00
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.